MYMerve Yuce

Merve Yuce

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Merve Yuce has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Multiscale Modeling of the Bacterial Ribosome to Identify Potential Peptide Modulators and Their Allosteric Effects

    by Merve Yuce, Fethiye Aylin Sungur, Ozge Kurkcuoglu

    The bacterial ribosome is a key antibiotic target, yet peptide-based modulation from its functional and allosteric sites is underexplored. We developed a computational pipeline combining SiteMap-derived binding-site detection, consensus docking with Glide and rDock, all-atom truncated molecular dynamics (MD), and coarse-grained MD (CGMD) simulations to identify peptide candidates against fourE. coliribosomal sites: the decoding center, peptidyl transferase center, a putative binding pocket on 30S, and the intersubunit bridge B8. Consensus-selected peptides recapitulated hallmark contacts of the native inhibitors viomycin and dalfopristin, and their interaction fingerprints delineate site-specific scaffolds that enable prioritization of inhibitor candidates with enhanced ribosomal affinity, thereby guiding the rational design of novel and effective peptide-based therapeutics. Notably, the peptide CycPeptMPDB_2508 exhibited binding affinity across all investigated sites, nominating it as a versatile lead core for antimicrobial peptide design. Dynamic cross-correlation matrices derived from CGMD simulations captured coupled motions between distal regions of the ribosome, while residue interaction network analysis identified hub residues enriched near the putative binding pocket and B8 bridge, outlining putative allosteric pathways linking local pockets to global motions relevant to decoding and domain closure. This work provides a concise, testable framework for ribosome-targeted peptide discovery and, to the best of our knowledge, constitutes the first ribosome–peptide virtual screening study to employ the viparr module for truncated ribosome–peptide complexes, suggesting the potential applicability of this approach to complex systems and broadening its scope.

  • Open Access

    A multi-stage computational pipeline and in vitro validation for the discovery of small-molecule translation inhibitors targeting the bacterial ribosome

    by Merve Yuce, Ezgi Koman, Fethiye Aylin Sungur, Ayten Yazgan-Karatas, Ozge Kurkcuoglu

    A hierarchical VS pipeline to target the bacterial ribosome PTC and in vitro translation assays identified Mitoxantrone as a potent inhibitor of E. coli protein synthesis, and Plerixafor, Olcegepant, and Ziritaxestat as lead compounds.


  • Computationally Efficient Network Models Successfully Predict Allosteric Sites of SARS ‐ CoV ‐2 Main Protease and Reveal Its Dynamic Allostery

    by Merve Yuce, Ozge Kurkcuoglu

    Developing allosteric drugs to treat pathogenic diseases can offer a promising alternative to orthosteric drugs that may bind to conserved motifs in human homologs. The allosteric drugs bind to allosteric sites, induce changes in the target protein's active site, and modulate its function with high selectivity, reduced adverse effects, and low toxicity. While identifying allosteric sites is costly and labor‐intensive with experimental approaches, computational methods utilizing three‐dimensional protein structures offer a cost‐effective solution for discovering potential allosteric sites and predicting the effects of ligand binding. This study evaluates the effectiveness of two network models, the residue interaction network (RIN) model and the mixed coarse‐grained anisotropic network model (mcgANM), in identifying putative allosteric regions, predicting the structural response of the protein to ligand binding, and elucidating allosteric mechanisms while maintaining computational efficiency. The SARS‐CoV‐2 main protease (M pro ) is employed as an allosteric protein model due to a rich experimental and computational data available since the COVID‐19 pandemic. The findings of the methods are assessed with statistical analysis, all‐atom molecular dynamics simulations, and other elastic network models, namely Essential Site Scanning Analysis and Gaussian Network Model using a dataset of 15 ligand‐bound and 4 ligand‐free structures. RIN predicted the known drug binding sites of M pro with high statistics, up to 80.0% sensitivity, 89.7% specificity, 29.6% precision, and 89.2% accuracy. RIN suggested an allosteric mechanism of M pro that facilitates the allosteric communication of the allosteric and active sites through residue fluctuations. RIN was able to decompose the enzyme structure to dynamic domains, showing the organization of structural components to form a functional viral protease. mcgANM suggested the changes in residue fluctuations after ligand binding. The findings underscore the utility of the network models in advancing allosteric drug design.


  • Open Access

    Repurposing of FDA‐approved drugs against active site and potential allosteric drug‐binding sites of COVID‐19 main protease

    by Merve Yuce, Erdem Cicek, Tugce Inan, Aslihan Basak Dag, Ozge Kurkcuoglu, Fethiye Aylin Sungur

    The novel coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) still has serious negative effects on health, social life, and economics. Recently, vaccines from various companies have been urgently approved to control SARS‐CoV‐2 infections. However, any specific antiviral drug has not been confirmed so far for regular treatment. An important target is the main protease (Mpro), which plays a major role in replication of the virus. In this study, Gaussian and residue network models are employed to reveal two distinct potential allosteric sites on Mpro that can be evaluated as drug targets besides the active site. Then, Food and Drug Administration (FDA)‐approved drugs are docked to three distinct sites with flexible docking using AutoDock Vina to identify potential drug candidates. Fourteen best molecule hits for the active site of Mpro are determined. Six of these also exhibit high docking scores for the potential allosteric regions. Full‐atom molecular dynamics simulations with MM‐GBSA method indicate that compounds docked to active and potential allosteric sites form stable interactions with high binding free energy (∆Gbind) values. ∆Gbind values reach −52.06 kcal/mol for the active site, −51.08 kcal/mol for the potential allosteric site 1, and − 42.93 kcal/mol for the potential allosteric site 2. Energy decomposition calculations per residue elucidate key binding residues stabilizing the ligands that can further serve to design pharmacophores. This systematic and efficient computational analysis successfully determines ivermectine, diosmin, and selinexor currently subjected to clinical trials, and further proposes bromocriptine, elbasvir as Mpro inhibitor candidates to be evaluated against SARS‐CoV‐2 infections.


  • Open Access

    Repurposing of FDA-approved Drugs against Active Site and Potential Allosteric Drug Binding Sites of COVID-19 Main Protease

    by Merve Yuce, Erdem Cicek, Tuğçe İnan, Aslıhan Başak Dağ, Özge Kürkçüoğlu, Fethiye Aylin Sungur

    The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) still has serious negative effects on health, social life, and economics. Recently, vaccines from various companies have been urgently approved to control SARS-CoV-2 infections. However, any specific antiviral drug has not been confirmed so far for regular treatment. An important target is the main protease (Mpro), which plays a major role in replication of the virus. In this study, Gaussian and residue network models are employed to reveal two distinct potential allosteric sites on Mpro that can be evaluated as drug targets besides the active site. Then, FDA-approved drugs are docked to three distinct sites with flexible docking using AutoDock Vina to identify potential drug candidates. 14 best molecule hits for the active site of Mpro are determined. 6 of these also exhibit high docking scores for the potential allosteric regions. Full-atom molecular dynamics simulations with MM-GBSA method indicate that compounds docked to active and potential allosteric sites form stable interactions with high binding free energy (∆Gbind) values. ∆Gbind values reach -52.06 kcal/mol for the active site, -51.08 kcal/mol for the potential allosteric site 1, and -42.93 kcal/mol for the potential allosteric site 2. Energy decomposition calculations per residue elucidate key binding residues stabilizing the ligands that can further serve to design pharmacophores. This systematic and efficient computational analysis successfully determines ivermectine, diosmin and selinexor currently subjected to clinical trials, and further proposes bromocriptine, elbasvir as Mpro inhibitor candidates to be evaluated against SARS-CoV-2 infection